Company: TELO
Filing Date: 2025-07-17
Form Type: 8-K
Source: 0001641172-25-020042
Chunk: 1

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-07-17
Form: 8-K
Item: Item 8.01
Chunk 1
---
and immunotherapy.

Telomere
length analysis in PC3 tumor tissue showed no measurable elongation following Telomir-1 administration. This finding is relevant given
concerns that telomere-targeting compounds may promote tumor progression through telomere extension in malignant cells. In contrast,
Telomir-1 demonstrated selective activity without altering telomere length in this model.

Telomir
is conducting ongoing research to evaluate Telomir-1 across multiple therapeutic areas, including oncology, Wilson’s disease, age-related
macular degeneration (AMD), autism spectrum disorder, and dysphonia. The company is continuing preclinical development across these programs
and plans to announce its initial IND indication at a future date.

“ We
remain encouraged by the preclinical data and continue to explore Telomir-1’s potential across several disease areas. Our team
is committed to advancing this program thoughtfully and strategically as we move toward clinical development,” said Erez Aminov,
CEO of Telomir.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                     TELOMIR                                       
  Dated:             By:                        /s/                
                     Name:                      Erez               
                     Title:                     Chief